CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease
2018 · American Journal of Kidney Diseases · 131 citations
https://doi.org/10.1053/j.ajkd.2018.07.020
V
Vimal K. Derebail
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
251
Papers
4.9K
Citations
39
h-index
84
i10-index
Vimal K. Derebail is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Hemoglobinopathies and Related Disorders & Renal Diseases and Glomerulopathies & Iron Metabolism and Disorders. The author has an h-index of 39, co-authored 214 publications.
ORCID: 0000-0002-7662-7497Papers by this author
worksEfficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)
2017 · Kidney International Reports · 47 citations
https://doi.org/10.1016/j.ekir.2017.02.019
Hemodialysis-Related Complement and Contact Pathway Activation and Cardiovascular Risk: A Narrative Review
2021 · Kidney Medicine · 37 citations
https://doi.org/10.1016/j.xkme.2021.04.006
Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity
2020 · Journal of Immunotherapy · 31 citations
https://doi.org/10.1097/cji.0000000000000338
Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study
2020 · Kidney International Reports · 26 citations
https://doi.org/10.1016/j.ekir.2020.06.041
Elevated Microparticle Tissue Factor Activity Differentiates Patients With Venous Thromboembolism in Anti-neutrophil Cytoplasmic Autoantibody Vasculitis
2019 · Kidney International Reports · 25 citations
https://doi.org/10.1016/j.ekir.2019.07.006
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat